Unlocking the full potential of stem cell therapies
Using umbilical cord stem cells for Immune disorders and tissue repair
Who we are
StemInov Innovation
A new Mesenchymal Stromal Cells (MSC) platform overcoming current cell therapy limitations and addressing strong unmet medical needs
Blockbuster potential in Community Acquired Pneumonia (CAP) associated with ARDS and sepsis with peak sales potential > $3B
Mesenchymal stem cells
A field with a few products approved but still largely constrained
There is a strong need for a reproducible and scalable bioproduction process capable of delivering homogeneous, high-potency, off-the-shelf MSC therapies that regulators, clinicians, and payers can trust.
Therapeutic
WhartSep®
The only treatment for severe CAP worsening to ARDS and sepsis
The therapy
A Wharton-jelly mesenchymal stem cell therapy
Documented safety, no clinical Phase I needed
Clinical
Severe CAP can progress to ARDS or sepsis with high-mortality
Phase IIa-ready by Q1-2027
Preclinical
Promising results in 3 preclinical models (mice, rabbits, pigs)
Better survival · Decreased inflammation · Lung protection · Decreased bacterial load
Partners
R&D
Support
Labels
